Stock Ratings | Bank of America raised its target price for ASML stock to $2,345; Baird raised its target price for Regenxbio (RGNX) stock to $32, with a potential upside of 252.81%
REGENXBIO, Inc. RGNX | 0.00 | |
Tenax Therapeutics, Inc. TENX | 0.00 | |
Nuvectis Pharma, Inc. NVCT | 0.00 | |
Altimmune Inc ALT | 0.00 | |
Owlet, Inc. Class A OWLT | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Baird: Maintaining its "Outperform" rating on Regenxbio ( REGENXBIO, Inc.(RGNX.US) ), while raising its price target from $27 to $32
Guggenheim: Maintaining a "buy" rating on Tenax Therapeutics ( Tenax Therapeutics, Inc.(TENX.US) ), while raising its price target from $34 to $40.
HC Wainwright & Co.: Maintaining a "buy" rating on Nuvectis Pharma ( Nuvectis Pharma, Inc.(NVCT.US) ), while raising the price target from $13 to $39.
Leerink Partners: Initial rating for Altimmune ( Altimmune Inc(ALT.US) ) at "outperforms the market," with a price target of $10.
TD Cowen: Maintaining Owlet's ( Owlet, Inc. Class A(OWLT.US) ) rating at "Buy", while lowering the target price from $13 to $10.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| REGENXBIO, Inc.(RGNX.US) | to lift | $32.0 | $9.07 | 252.81% | Baird |
| Tenax Therapeutics, Inc.(TENX.US) | to lift | $40.0 | $12.25 | 226.53% | Guggenheim |
| Nuvectis Pharma, Inc.(NVCT.US) | to lift | $39.0 | $16.53 | 135.93% | HC Wainwright & Co. |
| REGENXBIO, Inc.(RGNX.US) | to lift | $18.0 | $9.07 | 98.46% | Leerink Partners |
| Definium Therapeutics, Inc.(DFTX.US) | to lift | $60.0 | $36.67 | 63.62% | Oppenheimer |
| Altimmune Inc(ALT.US) | Initial classification | $10.0 | $2.93 | 241.3% | Leerink Partners |
| Owlet, Inc. Class A(OWLT.US) | cut | $10.0 | $5.08 | 96.85% | TD Cowen |
| Insmed Incorporated(INSM.US) | cut | $160.0 | $98.605 | 62.26% | Evercore ISI Group |
| Alamos Gold Inc.(AGI.US) | cut | $50.0 | $32.04 | 56.05% | B of A Securities |
| Accenture Plc Class A(ACN.US) | cut | $185.0 | $124.83 | 48.2% | Guggenheim |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Wells Fargo: Maintaining Applied Materials ( Applied Materials, Inc.(AMAT.US) ) rating at "overweight", while raising the price target from $520 to $715.
B of A Securities: Maintaining a "buy" rating on ASML Holding NV ADR(ASML.US) stock, while raising the price target from $2,268 to $2,345.
Stifel: Maintaining a "buy" rating on Credo Technology Group Credo Technology(CRDO.US) , raising the price target from $250 to $350.
Northland Capital Markets: Maintaining its "Outperform Market" rating for IonQ ( IonQ, Inc.(IONQ.US) ), while raising its price target from $55 to $70.
Cantor Fitzgerald: Maintaining a "neutral" rating on Qualcomm ( QUALCOMM Incorporated(QCOM.US) ) stock, while raising the price target from $150 to $200.
First Coverage
Oppenheimer: Initial rating for BridgeBio Oncology ( BridgeBio Oncology Therapeutics, Inc.(BBOT.US) ) at "outperforms the market", with a price target of $22.
Evercore ISI Group: Initial rating for Credo Technology Group Credo Technology(CRDO.US) ) stock at "outperform," with a target price of $325.
Citizens: Initial rating for NRC Health ( NRC Health(NRC.US) ) at "outperforms the market", with a price target of $23.
reduction
KGI Securities: Downgraded its rating on Apple Apple Inc.(AAPL.US) ) stock to "Hold", with a price target of $315.
Citigroup: Maintaining a "neutral" rating on FMC stock ( FMC Corporation(FMC.US) ), while lowering its price target from $17 to $14.
Keybanc: Maintaining its "Overweight" rating on ResMed ( ResMed Inc.(RMD.US) ), while lowering its price target from $290 to $266
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.